The objective of the study was to investigate the drug-drug interaction between LC15-0444 and metformin by comparing the pharmacokinetic/pharmacodynamic, safety, tolerability in healthy male subjets after oral administration concomitantly and each alone.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
30
Seoul National University Hospital
Seoul, South Korea
AUCτ,ss
To confirm and evaluate the pharmacokinetic characters of main metabolites of LC15-0444
Time frame: up to 171h30m
Cmax,ss
To confirm and evaluate the pharmacokinetic characters of main metabolites of LC15-0444
Time frame: up to 171h 30m
Vital signs
to measure Safety and tolerability of the investigational products
Time frame: up to 171h30m
AUECτ,ss
Compare the pharmacodynamic interaction between LC15-0444 and metformin in healthy male subjects This parameter is been used to measure DPP4 activity
Time frame: up to 171h30m
AUEC
Compare the pharmacodynamic interaction between LC15-0444 and metformin in healthy male subjects This parameter is been used to measure Active/total GLP-1, glucose, insulin, c-peptide, glucagon.
Time frame: up to 171h30m
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.